Du är här

2016-05-13

Phase Holographic: HoloMonitor technology facilitates cancer research at Florida International University

The first results of the ongoing collaboration between the Department
of Environmental and Occupational Health at Florida International
University (FIU) and Phase Holographic Imaging (PHI) were presented
in April at the annual meeting of the American Association for Cancer
Research (AACR).

Cancer stem cells are hypothesized by cancer researches to be the
"cancer seed" that causes cancer to spread. The inability to treat
metastatic cancer is believed to be a result of that current cancer
drugs where primarily developed to kill normal cancer cells, not the
cancer stem cells that spread the cancer to other parts of the body.
Due to that just a few metastatic cancer cells in the blood stream is
sufficient for the cancer to spread, there is today no diagnostic
method for detecting metastatic cancer before it is too late in most
cases.

The collaboration between FIU and PHI focus on the devastating
transformation of breast cells into metastatic cancer stem cells.
Spearheaded by Professor Deodutta Roy the researchers at FIU have
successfully used PHI's HoloMonitor® technology to study cancer stem
cells ability to move when affected by various cell signals.
Additionally, they have shown that these signals also affect the
transformation of breast cells into cancer stem cells and their
ability to form micro tumors. By interfering with these cell signals
the researcher's hope to develop new and improved cancer treatments.
For additional information regarding the collaboration see Fight
against cancer fueled by public-private collaborations
(http://breakthroughs.fiu.edu/2015/08/13/fight-against-cancer-fueled-by-p...)
and FIU's poster (http://www.phiab.se/publications/articles#das) at
AACR.

Professor Roy flanked by Dr. Quentin Felty and
Dr. Jayanta Das in front of their poster at
AACR.

"We are particularly encouraged by HoloMonitor's combined real-time
capabilities to study cell motility and 3-dimensional morphology of
living normal cells, breast cancer cells and cancer stem cells. We
are enthusiastic about continuing the collaboration and anticipate
that the HoloMonitor technology will contribute significantly to the
understanding of metastatic breast cancer progression and development
of novel early noninvasive diagnostic and prognostic biomarkers",
said Prof. Roy.

"It is deeply rewarding to see our HoloMonitor technology contributing
to cancer research. The technology's key strength is quantification
of single cell responses to stimuli without affecting the cells,
which is fundamental to reliably be able to study living cells", said
Peter Egelberg.

Links

· "About cancer stem cells
(http://www.cardiff.ac.uk/research/cancer-stem-cell/research/about-cancer...)"
by European Cancer Stem Cell Research Institute

For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74 | E-mail: peter.egelberg@phiab.se | Web:
www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development
of time-lapse cytometry instrumentation and software. With the first
instrument introduced in 2011, the company today offers a range of
products for long-term quantitative analysis of living cell dynamics
that circumvent the drawbacks of traditional methods requiring toxic
stains. Headquartered in Lund, Sweden, PHI trades through a network
of international distributors. Committed to promoting the science and
practice of time-lapse cytometry, PHI is actively expanding its
customer base and scientific collaborations in cancer research,
inflammatory and autoimmune diseases, stem cell biology, gene
therapy, regenerative medicine and toxicological studies.

-----------------------------------------------------------
http://news.cision.com/phase-holographic/r/holomonitor-technology-facili...
http://mb.cision.com/Main/11597/2008592/515408.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.